Cargando…
Access to Chagas disease treatment in the United States after the regulatory approval of benznidazole
Approximately 300,000 persons in the United States (US) are infected with Trypanosoma cruzi, the protozoan that causes Chagas disease, but less than 1% are estimated to have received antiparasitic treatment. Benznidazole was approved by the US Food and Drug Administration (FDA) for treatment of T. c...
Autores principales: | Yoshioka, Kota, Manne-Goehler, Jennifer, Maguire, James H., Reich, Michael R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7347212/ https://www.ncbi.nlm.nih.gov/pubmed/32569280 http://dx.doi.org/10.1371/journal.pntd.0008398 |
Ejemplares similares
-
Access to benznidazole for Chagas disease in the United States—Cautious optimism?
por: Alpern, Jonathan D., et al.
Publicado: (2017) -
The resilience of Triatoma dimidiata: An analysis of reinfestation in the Nicaraguan Chagas disease vector control program (2010–2016)
por: Yoshioka, Kota, et al.
Publicado: (2018) -
Estimating the Burden of Chagas Disease in the United States
por: Manne-Goehler, Jennifer, et al.
Publicado: (2016) -
1210. Recommendations for Screening and Diagnosis of Chagas Disease in the United States
por: Forsyth, Colin, et al.
Publicado: (2021) -
Recommendations for Screening and Diagnosis of Chagas Disease in the United States
por: Forsyth, Colin J, et al.
Publicado: (2021)